-  INCLUSION CRITERIA:

        NOTE: After approval and activation of Amendment D, patients who have failed this protocol
        treatment previously at the initial dose level may be eligible for re-enrollment and
        retreatment if they otherwise meet eligibility criteria.

          -  Patients greater than or equal to 18 years old with pathologically confirmed adult T-
             cell leukemia: smoldering or chronic, or previously treated lymphomatous or acute
             subtypes with clinically indolent behavior indicated by lack of significant symptoms
             and treatment free interval of greater than 6 monthsare eligible for treatment in the
             dose escalation and expansion cohorts.

          -  Patients must have serum antibodies directed to HTLV-1.

          -  Patients must have measurable or evaluable disease. Patients with > 10% of the PBMCs
             having the characteristic abnormal (i.e., CD3dim, CD4 plus CD25 plus expressing) FACS
             profile for circulating ATL cells will be considered to have evaluable disease.

          -  Patients must have adequate physiologic parameters:

          -  Absolute granulocyte count greater than or equal to 500 K/microL, platelet count
             greater than or equal to 75,000 K/microL and hemoglobin greater than or equal to 10
             g/dL.

          -  Bilirubin and creatinine less than or equal to 1.5 times institutional ULN.

          -  AST, ALT less than or equal to 3.0 times institutional ULN.

          -  Karnofsky Performance Score greater than or equal to 70% or ECOG less than or equal 1.

          -  Patients must be able to understand and sign Informed Consent Form.

        EXCLUSION CRITERIA:

          -  Patients with symptomatic leukemic meningitis, bony or GI tract involvement, serum
             calcium or LDH > 1.5 times the upper limit of normal will be excluded. However,
             patients that have both ATL and another HTLV-1 associated disease such as tropical
             spastic paraparesis (HAM/TSP) will be included.

          -  Patients with symptomatic leukemic meningitis, bony or GI tract involvement, serum
             calcium or LDH > 1.5 X the upper limit of normal will be excluded. However, patients
             that have both ATL and another HTLV-1 associated disease such as tropical spastic
             paraparesis (HAM/TSP) will be included.

          -  Patients who have received high doses of systemic corticosteroids for the treatment of
             their ATL within 4 weeks prior to the start of therapy.

          -  Patients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines or
             monoclonal antibodies in the 4 weeks prior to the start of the study.

          -  Life expectancy of less than 3 months.

          -  Documented active bacterial infections, HTLV-II infection, or hepatitis B or C as
             follows:

               -  A positive hepatitis B serology indicative of previous immunization (i.e., HBsAb
                  positive and HBc Ab negative), or a fully resolved acute hepatitis B infection is
                  not an exclusion criterion.

               -  Patients with an indolent chronic hepatitis B infection (normal ALT, AST, albumin
                  and no radiographic or biopsy evidence of cirrhosis) may be eligible.

               -  Patients with active hepatitis C are excluded. Patients positive for hepatitis C
                  virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is
                  negative for HCV RNA.

          -  Patients who have untreated human immunodeficiency virus (HIV) are not eligible for
             this study because by definition they have a defective immune response and are at much
             higher risk for opportunistic infections due to immune disregulation by both HTLV-1
             and HTLVIII (HIV) viruses. Patients on HIV therapy with undetectable viral loads as
             measured by HIV RNA quantitative real time PCR may be eligible.

          -  Inability or refusal to practice effective contraception during therapy. Men and women
             of childbearing potential must use an effective method of birth control or abstinence
             during treatment and for 1 week after completion of the treatment.

          -  Patient has significant and/or uncontrolled cardiac, renal, hepatic or other systemic
             disorders or significant psychological conditions at baseline visit that in the
             investigator s judgment would jeopardize subject enrollment or compliance with the
             study procedures.

          -  Patients with an absolute requirement for a medication that is a strong inhibitor of
             P450 CYP3A4 are not eligible.